Among them, tocilizumab is an anti-IL-6R monoclonal antibody (mAb), which has demonstrated clinical efficacy as an anti-COVID-19 drug by targeting the epigenetic inheritance of FOXP3+Tregs (222). The gene discussed is FOXP3; the disease is COVID-19.